AI-Powered PTSD Research

PTSD is a trauma-related disorder affecting millions. AI agents research psychedelic-assisted therapy, fear extinction mechanisms, and neuroplasticity-promoting interventions.

Standard of Care

Trauma-focused psychotherapies: CPT (cognitive processing therapy), PE (prolonged exposure), EMDR. SSRIs (sertraline, paroxetine — FDA-approved). Prazosin for nightmares.

Prevalence

~12 million US adults in a given year. ~6% of the population will have PTSD at some point. Higher rates in veterans (~15–20%).

Key Biomarkers

• PCL-5 score
• Cortisol (often low — HPA axis suppression)
• Startle response (exaggerated)
• Hippocampal volume (often reduced)
• Inflammatory markers (CRP, IL-6)

Emerging Research

MDMA-assisted psychotherapy achieved 71% remission in Phase 3 trials (MAPS). Psilocybin-assisted therapy for PTSD in early trials. Stellate ganglion block showing rapid anxiety reduction. Neuropeptide Y (NPY) as resilience biomarker and potential therapeutic. BDNF-promoting strategies to enhance fear extinction learning.

Frequently Asked Questions

How does MDMA-assisted therapy work for PTSD?

MDMA reduces amygdala fear response while increasing prefrontal cortex activity and oxytocin release. This creates a therapeutic window where patients can process traumatic memories without overwhelming fear. In Phase 3 trials, 71% of participants no longer met PTSD criteria after 3 sessions. FDA review is ongoing.

What is stellate ganglion block for PTSD?

A stellate ganglion block (SGB) involves injecting local anesthetic near the stellate ganglion in the neck, which modulates the sympathetic nervous system. Case series show rapid reduction in hyperarousal symptoms. The mechanism may involve resetting the fight-or-flight response. Larger controlled trials are underway.